Business
Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022
Total of 54 million doses to be supplied to COVAX in 2021 New 2022 supply agreement: 20 million additional doses purchased for supply in Q2 for total of
About this update from Moderna, Inc.
[{"type":"text","content":"\nTotal of 54 million doses to be supplied to COVAX in 2021\n\nNew 2022 supply agreement: 20 million additional doses purchased for supply in Q2 for total of 136.5 million doses; Gavi retains option for additional 30 million in Q2 and 100 million in Q3 2022\n\nGavi now retains the option to procure a total of up to 650 million doses in 2021 and 2022\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nModerna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to accelerate supply of 20 million doses to COVAX by December 31, 2021 for a total of 54 million doses made available to COVAX in 2021. Deliveries to COVAX Advance Market Commitment (AMC) countries have already begun.\n\nThese doses are included in Moderna’s previously announced agreement with Gavi and were originally scheduled for delivery in the first quarter of 2022. Given the acceleration into 2021, Moderna expects to supply up to 96.5 million doses in the first quarter of 2022 and an additional 116.5 million doses in the second quarter of 2022. Gavi retains the option to procure 233 million additional doses in 2022 under the original agreement.\n\nModerna is also announcing a new supply agreement with Gavi for an additional 20 million doses for delivery in the second quarter of 2022 for a total of up to 136.5 million doses in the second quarter of 2022. Gavi retains options to purchase an additional 30 million doses in the second quarter of 2022 and an additional 100 million doses in the third quarter of 2022. Together, these two agreements allow Gavi to purchase up to 650 million doses of the Moderna COVID-19 vaccine for delivery through 2022.\n\n“I would like to thank our partners at Gavi and COVAX for their work and collaboration to reach this agreement. This is another important milestone as we work to ensure that people around the world have access to our COVID-19 vaccine as quickly as possible,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We are proud that our agreement is the largest direct supply agreement with COVAX among U.S. authorized suppliers. We remain committed to implementing a comprehensive strategy to ensure that low-income countries get access to our vaccine as we seek to help end the pandemic around the wor...